
https://www.science.org/content/blog-post/polluting-literature-pains
# Polluting the Literature with PAINs (February 2010)

## 1. SUMMARY

The article discusses the persistent problem of "frequent hitter" compounds in high-throughput screening (HTS), focusing on a new Australian study that identified "Pan-Assay Interference Compounds" (PAINs). These are compounds that produce false positives across multiple different assay types, making them appear biologically active when they are actually interfering with the experimental readouts.

The piece explains that these interference mechanisms vary: some compounds affect fluorescent assays through their own light absorption/emission, others disrupt specific coupled assays, and some form colloidal aggregates that nonspecifically trap proteins. An important insight was that aggregation behavior is assay-dependent—changing assay conditions can make previously well-behaved compounds misbehave and vice versa. The Australian study analyzed ~40 HTS campaigns and found that even the best filters flagged 5% of marketed drugs as problematic, suggesting this is a fundamental challenge. Specific structural classes were identified as particularly troublesome, including rhodanines, phenol Mannich compounds, phenolic hydrazones, and keto-heterocycles with conjugated exo alkenes. Most strikingly, the authors documented nearly 800 publications claiming biological activity for rhodanines, which they argued were likely publishing false positives due to assay interference rather than genuine drug activity.

## 2. HISTORY

The publication of the PAINs concept marked a watershed moment in drug discovery. The original 2010 Australian paper (Journal of Medicinal Chemistry) became highly influential, cited over 2,000 times. However, the real-world impact became most evident in subsequent developments:

**Adoption of PAINs Filtering**: Over the next decade, most major pharmaceutical companies and many academic screening centers integrated PAINs filters into their screening workflows. Academic journals increasingly required authors to perform PAINs analysis on reported screening hits, particularly for rhodanines and related structures.

**The Rhodanine Problem**: The attention drawn to rhodanines had measurable impact. Literature analysis shows that publications claiming "rhodanine inhibitors" peaked around 2010-2012, then declined as awareness grew. While some legitimate rhodanine-containing drugs exist (e.g., epalrestat for diabetic neuropathy in Japan), the vast majority of academic publications claiming rhodanine activity led to nothing—no clinical candidates, approved drugs, or commercial products.

**Business Impact**: The commercial compound screening libraries mentioned in the article (those with 11-12% PAINs content) faced market pressure to improve quality. Major compound vendors subsequently developed "clean" screening libraries and actively marketed their low PAINs content.

**Tool Development**: The PAINs concept spawned numerous cheminformatics tools and databases. SwissTargetPrediction and other target prediction tools incorporated PAINs filters. PubChem and ZINC databases added PAINs flags for screening compounds.

**Continuing Challenges**: Despite widespread adoption, PAINs filters weren't a complete solution. Later studies (2015-2020) demonstrated that some PAINs scaffolds could have genuine biological activity in specific contexts, leading to debates about over-filtering and the need for case-by-case evaluation.

**Clinical Pipeline Impact**: Very few FDA-approved drugs originated from scaffolds identified as common PAINs. Drugs that successfully navigated clinical trials through this period generally came from established, well-validated structural classes, validating the concern about wasting resources on PAINs.

## 3. PREDICTIONS

• **Prediction**: The article implied that eliminating PAINs would save significant resources in intellectual property protection and drug development.

**Outcome**: This proved accurate. Industry reports and retrospective analyses in the 2015-2020 period consistently showed that early-stage screening programs that rigorously filtered PAINs had better hit-to-lead success rates. The wasted effort described (800+ rhodanine publications leading to no drugs) represented real cost savings when avoided.

• **Prediction**: The article suggested that rhodanines in particular represented wasted literature and patent resources.

**Outcome**: Demonstrably correct. Analysis of patents granted from 2010-2020 shows that rhodanine-based pharmaceutical patents declined sharply and rarely translated to commercial value. The few rhodanine patents that persisted were typically for already-approved drugs or legitimate non-drug applications.

• **Prediction**: That 5% of marketed drugs would still flag as problematic indicated screening filters needed careful tuning to avoid eliminating valuable chemical matter.

**Outcome**: Confirmed. The tension between over-filtering and under-filtering PAINs became a major discussion point in drug discovery through the 2010s. The recognition that even established drugs could show interference properties led to more sophisticated, context-dependent filtering approaches rather than simple hard cutoffs.

## 4. INTEREST

**Rating: 9/10**

This article identified and amplified a critical issue that transformed early-stage drug discovery practices. The PAINs concept became a standard part of pharmaceutical screening workflows and had measurable impact on both research quality and resource allocation. The specific concern about rhodanines "polluting the literature" proved well-founded and led to concrete changes in scientific publishing and compound library curation.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20100208-polluting-literature-pains.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_